Technology area: Biotechnology & Pharmaceuticals
57 pending office actions • 21 clients • 54 examiners • 38 art units • 0 of 57 (0%) have an AI response strategy ready
VIKSNINS HARRIS PADYS MALEN LLP reports 63 pending office actions in Biotechnology & Pharmaceuticals and 3309 career applications. The application volume provides substantial context for the active examination docket.
The resolved allowance rate is 76.5%, with an average of 3.45 office actions per allowance. The rate describes resolved outcomes, while the action average indicates that allowance commonly follows several examination events.
Based on the USPTO statutory response window for each pending office action. 16 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 16 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (9%) |
| §103 only | 15 (26%) |
| §112 only | 4 (7%) |
| Double-patenting only | 2 (4%) |
| Double-patenting + other | 6 (11%) |
| Multi-statute (no §101) | 24 (42%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAUN, MADELINE E | 2 | 68.4% | +25.3% |
| BURKETT, DANIEL JOHN | 2 | 63.4% | +33.2% |
| GWARTNEY, ELIZABETH A | 2 | 36.0% | +34.9% |
| NUR, ABDULLAHI | 1 | 88.2% | +6.1% |
| HASTINGS, ALISON AZAR | 1 | 62.5% | +42.1% |
| ORKIN, ALEXANDER J | 1 | 65.4% | +26.9% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| JACKSON III, WALTER | 1 | 50.0% | +0.0% |
| ROBINSON, KEITH O NEAL | 1 | 91.6% | +3.8% |
| HIRAKIS, SOPHIA P | 1 | 57.4% | +69.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19228322 | HYPERSPECTRAL IMAGING FOR EARLY DETECTION OF ALZHEIMER'S DISEASE | NUR, ABDULLAHI | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18110292 | METHOD FOR PREPARING ACTIVATED CARBON | MENON, KRISHNAN S | 191d overdue |
| 18634406 | SYNTHETIC GENOMIC SAFE HARBORS AND METHODS THEREOF | SULLIVAN, STEPHANIE LAUREN | 131d overdue |
| 18276823 | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF | LU, CHENG | 46d |
| 17923171 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | SCHACHERMEYER, SAMANTHA LYNN | 65d |
| 18277444 | ARTIFICIAL DNA REPLISOME AND METHODS OF USE THEREOF | FRONDA, CHRISTIAN L | 70d |
| 18010108 | BIOMARKER COMBINATIONS FOR DETERMINING AGGRESSIVE PROSTATE CANCER | POHNERT, STEVEN C | 77d |
| 18274907 | A PROCESS FOR PREPARING A VEGAN EDIBLE PRODUCT FROM EDIBLE NON-ANIMAL PROTEINS | BEKKER, KELLY JO | 84d |
| 19053009 | COMPOUNDS AND METHODS FOR TREATING CHEMOTHERAPY-INDUCED PAIN | BRAUN, MADELINE E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18274863 | A PROCESS FOR PREPARING A VEGAN EDIBLE PRODUCT FROM EDIBLE NON-ANIMAL PROTEINS | GWARTNEY, ELIZABETH A | 35d overdue |
| 19191629 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF AN AAK1 INHIBITOR | HASTINGS, ALISON AZAR | — |
| 19184578 | PULMONARY ARTERY FLOW RESTRICTOR | ORKIN, ALEXANDER J | — |
| 19053009 | COMPOUNDS AND METHODS FOR TREATING CHEMOTHERAPY-INDUCED PAIN | BRAUN, MADELINE E | — |
| 18958741 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | BURKETT, DANIEL JOHN | — |
| 18859673 | NEXT GENERATION DIPROVOCIMS THAT ACTIVATE THE INNATE AND ADAPTIVE IMMUNE RESPONSE | HIRAKIS, SOPHIA P | — |
| 18838564 | FILLED FOOD PRODUCTS AND METHODS OF PREPARING SAME | GWARTNEY, ELIZABETH A | — |
| 18546217 | SMALL MOLECULE ACTIVATORS OF YAP TRANSCRIPTIONAL ACTIVITY FOR REGENERATIVE ORGAN REPAIR | BRAUN, MADELINE E | — |
| Art Unit | Apps |
|---|---|
| 1629 | 4 |
| 1625 | 3 |
| 1624 | 3 |
| 1627 | 2 |
| 1623 | 2 |
| 1613 | 2 |
| 1759 | 2 |
| 1693 | 2 |
| 1635 | 2 |
| 1699 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19228322 | HYPERSPECTRAL IMAGING FOR EARLY DETECTION OF ALZHEIMER'S DISEASE | Regents Of The University Of Minnesota | NUR, ABDULLAHI | 2877 | §103Other | Non-Final OA | — | Pending | Jun 04, 2025 |
| 19191629 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF AN AAK1 INHIBITOR | Lexicon Pharmaceuticals, Inc. | HASTINGS, ALISON AZAR | 1627 | DP | Non-Final OA | — | Pending | Apr 28, 2025 |
| 19184578 | PULMONARY ARTERY FLOW RESTRICTOR | Regents Of The University Of Minnesota | ORKIN, ALEXANDER J | 3771 | §103 | Final Rejection | — | Pending | Apr 21, 2025 |
| 19070289 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. | SEAMAN, D MARGARET M | 1625 | DP | Non-Final OA | — | Pending | Mar 04, 2025 |
| 19053009 | COMPOUNDS AND METHODS FOR TREATING CHEMOTHERAPY-INDUCED PAIN | Lexicon Pharmaceuticals, Inc. | BRAUN, MADELINE E | 1624 | §102§103Other | Non-Final OA | — | Pending | Feb 13, 2025 |
| 18997744 | TGFB TREATMENT OF ORGANOID CULTURES TO PRIME FOR REGENERATIVE THERAPY OF DAMAGED GI EPITHELIA | Rutgers, The State University Of New Jersey | JACKSON III, WALTER | 1638 | §103 | Non-Final OA | — | Pending | Jan 22, 2025 |
| 18961937 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS BY VIRUS PARTICLES IN PLANTS | The Regents of the University of California | ROBINSON, KEITH O NEAL | 1661 | §103§112Other | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18958741 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | Taxis Pharmaceuticals, Inc. | BURKETT, DANIEL JOHN | 1625 | §102§112DP | Non-Final OA | — | Pending | Nov 25, 2024 |
| 18859673 | NEXT GENERATION DIPROVOCIMS THAT ACTIVATE THE INNATE AND ADAPTIVE IMMUNE RESPONSE | The Board Of Regents Of The University Of Texas System | HIRAKIS, SOPHIA P | 1623 | §102§112 | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18852384 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | The Regents of the University of California | BERRIOS, JENNIFER A | 1613 | §101§103§112 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18897158 | METHODS OF TREATING TYPE 1 DIABETES AND KIDNEY DISEASE | Lexicon Pharmaceuticals, Inc. | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §102§103§112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18846873 | THERAPEUTIC COMPOUND AND SALTS | Regents Of The University Of Minnesota | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §102§103§112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18838564 | FILLED FOOD PRODUCTS AND METHODS OF PREPARING SAME | Yb Foods LLC | GWARTNEY, ELIZABETH A | 1759 | §103 | Non-Final OA | — | Pending | Aug 14, 2024 |
| 18724911 | METHODS FOR IMPROVING PROTEIN DELIVERY TO PLANT CELLS BY BIOLISTICS | The Regents of the University of California | SHEN, YANXIN NMN | 1663 | §103§112 | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18722252 | ANTI-MASP-2 ANTIBODY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shenyang Sunshine Pharmaceutical Co., Ltd. | STEPHENS, AMELIA CAROLE | 1645 | §102§103§112Other | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18669075 | BIOMARKERS AND METHODS FOR DETECTION OF SEIZURES AND EPILEPSY | Cognizance Biomarkers, Inc. | ORWIG, KEVIN S | 3991 | Other | Non-Final OA | — | Pending | May 20, 2024 |
| 18662929 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. | SHIAO, REI TSANG | 1691 | §112DP | Non-Final OA | — | Pending | May 13, 2024 |
| 18648062 | THERAPEUTIC COMPOUNDS | Rutgers, The State University Of New Jersey | CORNET, JEAN P | 1628 | §102§103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18705175 | TOLL-LIKE RECEPTOR AGONISTS AND ANTAGONISTS AND USES THEREOF | Regents Of The University Of Minnesota | ONDACHI, PAULINE WANJIKU MUCH | 1627 | §103DP | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18633908 | THERAPEUTIC COMPOUNDS | Regents Of The University Of Minnesota | MILLER, DALE R | 1693 | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18634406 | SYNTHETIC GENOMIC SAFE HARBORS AND METHODS THEREOF | The Regents of the University of California | SULLIVAN, STEPHANIE LAUREN | 1635 | §102§103 | Final Rejection | 131d overdue | Pending | Apr 12, 2024 |
| 18700140 | IMPROVED CEREBRAL ANGIOGRAPHY CATHETER | Rutgers, The State University Of New Jersey | FERNANDEZ, KATHERINE L | 3798 | §103 | Non-Final OA | — | Pending | Apr 10, 2024 |
| 18613381 | USE OF SOTAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES MELLITUS | Lexicon Pharmaceuticals, Inc. | CRAIGO, BAHAR ALAWI | 1699 | §101§102§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18593314 | CONJUGATES AND METHODS OF USE THEREOF | Regents Of The University Of Minnesota | BOWERS, ERIN M | 1653 | §102§103 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18683583 | DUAL-TARGETED RNA POLYMERASE INHIBITORS: CONJUGATES OF BENZOXAZINO- AND SPIRO-RIFAMYCINS WITH N ALPHA-AROYL-N-ARYL-PHENYLALANINAMIDES | Rutgers, The State University Of New Jersey | SEITZ, ANTHONY JOSEPH | 1629 | §103§112Other | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18424215 | FORTIFIED CONFECTION COMPOSITIONS | Glanbia Dairy Nutrition Limited | STULII, VERA | 1791 | §102§112 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18403891 | HIGHLY FLUORINATED COMPOUNDS FOR 19F MRI-BASED THERMOMETRY | Regents Of The University Of Minnesota | BRAZIN, JACQUELINE | 1798 | §102§112 | Non-Final OA | — | Pending | Jan 04, 2024 |
| 18572411 | THERAPEUTIC COMPOUNDS | Taxis Pharmaceuticals, Inc. | CHENG, KAREN | 1623 | §102§103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18517049 | PHARMACOLOGICAL DEPLETION OF HEME FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME | The Scripps Research Institute | NEAGU, IRINA | 1629 | §102§103 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18381799 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. | SONG, JIANFENG | 1613 | §103Other | Final Rejection | — | Pending | Oct 19, 2023 |
| 18286955 | Glycan Targets of Serum IgG and IgM Antibodies | Regents Of The University Of Minnesota | WEN, SHARON X | 1641 | §103 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18372535 | CATALYSTS | The Regents of the University of California | SPIES, BRADLEY R | 1742 | §102§103 | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18283071 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. | METCALF, MATTHEW CURRAN | 1647 | §103DP | Non-Final OA | — | Pending | Sep 20, 2023 |
| 18548635 | HETEROBIFUNCTIONAL COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION AND METHODS FOR THEIR USE | The Scripps Research Institute | CHANDRAKUMAR, NIZAL S | 1625 | §103§112 | Final Rejection | — | Pending | Sep 01, 2023 |
| 18279380 | METHODS OF ENHANCING ANTIBODY THERAPIES | UNIVERSITY OF IOWA RESEARCH FOUNDATION | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §112 | Final Rejection | 23d overdue | Pending | Aug 29, 2023 |
| 18277444 | ARTIFICIAL DNA REPLISOME AND METHODS OF USE THEREOF | Regents Of The University Of Minnesota | FRONDA, CHRISTIAN L | 1652 | §103§112 | Non-Final OA | 70d | Pending | Aug 16, 2023 |
| 18546217 | SMALL MOLECULE ACTIVATORS OF YAP TRANSCRIPTIONAL ACTIVITY FOR REGENERATIVE ORGAN REPAIR | The Scripps Research Institute | BRAUN, MADELINE E | 1624 | §103§112 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 18276823 | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF | Denali Therapeutics Inc. | LU, CHENG | 1642 | §102§103§112Other | Non-Final OA | 46d | Pending | Aug 10, 2023 |
| 18228422 | SELECTIVE BRD4-DEGRADER MOLECULES | Regents Of The University Of Minnesota | BURKETT, DANIEL JOHN | 1624 | §112 | Non-Final OA | — | Pending | Jul 31, 2023 |
| 18274863 | A PROCESS FOR PREPARING A VEGAN EDIBLE PRODUCT FROM EDIBLE NON-ANIMAL PROTEINS | BK Giulini GmbH | GWARTNEY, ELIZABETH A | 1759 | §103 | Final Rejection | 35d overdue | Pending | Jul 28, 2023 |
| 18274907 | A PROCESS FOR PREPARING A VEGAN EDIBLE PRODUCT FROM EDIBLE NON-ANIMAL PROTEINS | BK Giulini GmbH | BEKKER, KELLY JO | 1792 | §103§112 | Final Rejection | 84d | Pending | Jul 28, 2023 |
| 18274412 | INHIBITION OF DEGRANULATION OF NEUTROPHIL CELLS IN COVID-19 PATIENTS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | BANERJEE, KOYELI | 1658 | §103 | Final Rejection | 13d | Pending | Jul 26, 2023 |
| 18270162 | SENSE,SUPPRESSOR TRANSFER RNA COMPOSITIONS AND RELATED USES AND FUNCTIONS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | GROOMS, TIFFANY NICOLE | 1637 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18035695 | TARGETED CONJUGATES COMPRISING MODIFIED SIRNA | Arbutus Biopharma Corporation | TATGE, LEXUS MARC | 1637 | §102§103§112DP | Non-Final OA | — | Pending | May 05, 2023 |
| 18141728 | MASKED SINGLE-DOMAIN ANTIBODIES AND METHODS THEREOF | Regents Of The University Of Minnesota | TAYLOR, LIA ELAN | 1641 | §112 | Final Rejection | 19d | Pending | May 01, 2023 |
| 18032768 | METHODS FOR IMPROVING PLANT GROWTH AND CROP YIELD BY USING COMPOUNDS OF TRISULPHIDE OR TETRASULPHIDE | UNIVERSITY OF IOWA RESEARCH FOUNDATION | PAK, JOHN D | 1699 | §102§103§112 | Non-Final OA | — | Pending | Apr 19, 2023 |
| 18120204 | MICRORNA INHIBITOR SYSTEM AND METHODS OF USE THEREOF | UNIVERSITY OF IOWA RESEARCH FOUNDATION | MEYERING, SHABANA SHABBEER | 1635 | §101§112 | Non-Final OA | — | Pending | Mar 10, 2023 |
| 18110292 | METHOD FOR PREPARING ACTIVATED CARBON | The Regents of the University of California | MENON, KRISHNAN S | 1777 | §102§103 | Final Rejection | 191d overdue | Pending | Feb 15, 2023 |
| 18017541 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. | DAHLIN, HEATHER RAQUEL | 1629 | §112 | Final Rejection | 2d overdue | Pending | Jan 23, 2023 |
| 18010108 | BIOMARKER COMBINATIONS FOR DETERMINING AGGRESSIVE PROSTATE CANCER | Minomic International Ltd. | POHNERT, STEVEN C | 1683 | §101§103§112Other | Non-Final OA | 77d | Pending | Dec 13, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial76.5% of resolved applications prosecuted by Viksnins Harris Padys Malen LLP were allowed, across 3,309 applications in USPTO records.
3.45 office actions per allowed application on average.
57 pending office actions as of October 2026, for 21 clients, before 54 examiners in 38 art units.
